Intravitreal inserts of steroids to treat diabetic macular edema

Current Diabetes Reviews

Volumn 5, Issue 1, 2009, Pages 26-32

  Montero, Javier A ^a   Ruiz Moreno, José Ma ^a,b  

^a Vitreo Retinal Unit   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Dexamethasone inserts; Diabetic macular edema; Drug delivery system; Fluocinolone inserts; Intravitreal triamcinolone; Steroids

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PLACEBO; STEROID; TRIAMCINOLONE ACETONIDE; DRUG DERIVATIVE; FLUOCINOLONE; GLUCOCORTICOID; TRIAMCINOLONE;

CATARACT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENDOPHTHALMITIS; HUMAN; INFECTION; INTRAOCULAR HYPERTENSION; LASER COAGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA TEAR; REVIEW; SPINAL CORD INJURY; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; UVEITIS; VISUAL IMPAIRMENT; VITREORETINOPATHY; VITREOUS HEMORRHAGE; DIABETIC ANGIOPATHY; DOSE RESPONSE; DRUG EFFECT; PATHOLOGY; VITREOUS BODY;

DEXAMETHASONE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; TRIAMCINOLONE; VITREOUS BODY;

EID: 65549117729     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909787314211     Document Type: Review

References (64)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-74.
2. Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology 1992; 99: 58-62.
3. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-56.
4. Cunha-Vaz J. Diabetic macular edema. Eur J Ophthalmol 1998; 8: 127-30.
5. Asensio Sanchez VM, Corral Azor A, Aguirre Aragon B, De Paz Garcia M. [Glutamate concentration in diabetic vitreous]. Arch Soc Esp Oftalmol 2003; 78: 493-7.
6. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283-90.
7. Smith RT, Lee CM, Charles HC, Farber M, Cunha-Vaz JG. Quantification of diabetic macular edema. Arch Ophthalmol 1987; 105: 218-22.
8. Mirza RG, Johnson MW, Jampol LM. Optical coherence tomography use in evaluation of the vitreoretinal interface: a review. Surv Ophthalmol 2007; 52: 397-421.
9. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-806.
10. Bresnick GH. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 1983; 90: 1301-17.
11. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998; 47: 1953-9.
12. Funatsu H, Yamashita H, Ikeda T, et al. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 2003; 135: 321-7.
13. Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002; 133: 537-3.
14. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725-30.
15. Lamberton RP, Goodman AD, Kassoff A, et al. Von Willebrand factor (VIII R:Ag), fibronectin, and insulin-like growth factors I and II in diabetic retinopathy and nephropathy. Diabetes 1984; 33: 125-9.
16. Peters S, Cree IA, Alexander R, et al. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine 2007; 40: 144-50.
17. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 4295-1.
18. Jonas JB, Neumaier M. Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 2007; 39: 139-42.
19. Grant MB, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004; 13: 1275-93.
20. Shimizu E, Funatsu H, Yamashita H, Yamashita T, Hori S. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol 2002; 46: 78-83.
21. Awata T, Kurihara S, Takata N, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005; 333: 679-85.
22. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
23. Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica 2007; 221: 118-31.
24. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-9.
25. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-17.
26. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol 2005; 89: 321-6.
27. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61.
28. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: 171-80.
29. Goff MJ, Jumper JM, Yang SS, et al. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006; 26: 896-901.
30. Dada T, Dhawan M, Garg S, Nair S, Mandal S. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract. J Cataract Refract Surg 2007; 33: 1613-8.
31. Morrison VL, Kozak I, LaBree LD, et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 2007; 114: 334-9.
32. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006; 142: 794-99.
33. Chu YK, Chung EJ, Kwon OW, Lee JH, Koh HJ. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye 2008; 22: 895-9.
34. Jonas JB, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004; 138: 1054-5.
35. Inoue M, Takeda K, Morita K, et al. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004; 138: 1046-8.
36. Baath J, Ells AL, Crichton A, Kherani A, Williams RG. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007; 23: 304-10.
37. Gillies MC, Islam FM, Zhu M, Larsson J, Wong TY. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007; 91: 1323-6.
38. Lee VHL, Pince KJ, Frambach DA, Martini B. Drug delivery to the posterior segment, in Ogden TE, Schachat AP, Eds. Retina, CV Mosby: St Louis, Mo. 1989, p. 483-98.
39. Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994; 8(Pt 1): 66-9.
40. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992; 110: 259-66.
41. Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol 1991; 15: 233-5.
42. Visscher GE, Robison RL, Maulding HV, et al. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) micro-capsules. J Biomed Mater Res 1985; 19: 349-65.
43. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88: 344-7.
44. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-4.
45. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci 2005; 46: 4336-41.
46. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005; 46: 1062-8.
47. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006; 124: 1012-8.
48. Srivastava S, Mruthunjaya P, Wiser J, et al. Intravitreal sustained-release fluocinolone acetonide device to treat severe experimental uveitis. Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 3536.
49. Mruthyunjaya P, Tseng W, Stinnett S, Ashton P, Jaffe GJ. Fluocinolone acetonide sustained drug delivery system in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2002; 43: E-Abstract 3003.
50. Wong KR, Glybina IV, Buddi R, et al. Pharmacological effects of intravitreal fluocinolone acetonide in RCS rats with chronic subretinal prosthesis implants. Abstract ARVO 2005: #1510.
51. Glybina IV, Iezzi R, Ashton P, Abrahms G. Neuroprotective properties of fluocinolone acetonide chronically delivered into the vitreous of albino RCS rats Abstract ARVO 2006: # 1028.
52. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004; 20: 269-75.
53. See RF, Peairs JJ, Srivastava S, et al. Safety and drug device profile of injectable intravitreal sustained-release fluocinolone acetonide device. ARVO Abstract 2006: # 5119.
54. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41: 3569-75.
55. Casto BC. Detection of chemical carcinogens and mutagens in hamster cells by enhancement of adenovirus transformation. In: Mishra N, Dunlul V, Melman M, Eds. Advances in Modern Environmental Toxicology, Mammalian Cell Transformation by Chemical Carcinogens, Senate Press, Princeton Junction, NJ, 1980, Vol. 1, p. 241-271.
56. Schwarz JA, Viaje A, Slaga TJ. Fluocinolone acetonide: a potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem Biol Interact 1977; 17: 331-47.
57. Pearson P, Lery BL, Comstock T. Fluocinolone Acetonide Implant Study Group, Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3 year results of a multi-center clinical trial. ARVO Abstract 2006: # 5442.
58. Pearson PA, Baker CW, Eliott D, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: 2 year results. Invest Ophthalmol Vis Sci 2004; 4 S: 1111.
59. Pearson PA, Baker CW, Elliot D, et al. Fluocinolone acetonide intravitreal implant in subjects with diabetic macular edema: 12 month results. Invest Ophthalmol Vis Sci 2003; 44: E-Abstract 4288.
60. Jaffe GJ, Fluocinolone-Acetonide-Uveitis-Study-Group. Fluocinolone acetonide intravitreal implant for uveitis affecting the posterior segment of the eye. Invest Ophthalmol Vis Sci 2004; 45: E-Abstract 3369.
61. Jaffe GJ, Guo JB-NH, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107: 2024-33.
62. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-7.
63. Ramchandran RS, Stinett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic retinal venous occlusive disease. ARVO Abstract 2006: # 5907.
64. Denny JP, Carlson A, McCallum R, et al. Combined fluocinolone acetonide sustained drug delivery system implantation and phaeoemulsification/intraocular lens implantation in patients with severe uveitis. Invest Ophthalmol Vis Sci 2003; 44: E-Abstract 2410.